RxDoctor Payments Data

Amanda Lind

Nurse Practitioner · Pittsburgh, PANPI 1841931748

Payments from drug & device makers

$1,711in general payments, 2019–2025

Across 84 payments — averaging $20.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$437
  • Alkermes, Inc.$257
  • Otsuka America Pharmaceutical, Inc.$229
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$169
  • Lundbeck LLC$94
  • Axsome Therapeutics, Inc.$92
  • plus $433 from 10 others

What the payments were for

  • Food & beverage$1,66297%
  • Education$493%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,711 in reported general payments places this provider in the 85th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$2,378
Medicare patients
16
Services billed
23

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate28$227,718
RexultiBrexpiprazole24$35,101
LybalviOlanzapine/Samidorphan Malate19$30,759
AuvelityDextromethorphan Hbr/Bupropion20$22,360
Lisdexamfetamine Dimesylate35$9,689
Chlorpromazine Hcl13$9,322
Bupropion XlBupropion Hcl179$8,024
VyvanseLisdexamfetamine Dimesylate14$5,080
Aripiprazole126$4,546
Venlafaxine Hcl ErVenlafaxine Hcl91$4,166
Asenapine Maleate26$3,660
Zolpidem Tartrate61$2,900
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine48$2,769
Duloxetine Hcl133$2,509
Lamotrigine127$2,268

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$73$227,71828 claims
Otsuka America Pharmaceutical, Inc.Rexulti$229$35,10124 claims
Alkermes, Inc.Lybalvi$257$30,75919 claims
Axsome Therapeutics, Inc.Auvelity$92$22,36020 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$65$5,08014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →